Infliximab and adalimumab inhibit which cytokine to treat autoimmune conditions?

Infliximab and adalimumab are monoclonal antibodies that target and inhibit tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine involved in systemic inflammation. By neutralizing TNF-α, these medications help reduce inflammation and have proven effective in treating various autoimmune conditions, such as rheumatoid arthritis, Crohn's disease, and psoriasis. This inhibition leads to decreased inflammatory responses that can contribute to the symptoms and progression of these diseases, making TNF-α a crucial target for therapeutic intervention in autoimmune disorders. Other cytokines listed, such as IL-6, IL-1, and IL-10, are involved in different aspects of immune function and inflammation but are not the primary targets of infliximab and adalimumab.